The Rivastigmine Market continues to expand steadily as the global burden of Alzheimer's disease and Parkinson's disease dementia intensifies, driving sustained demand for effective cholinesterase inhibitor therapies. With dementia affecting over 55 million people worldwide and numbers projected to triple by 2050, the need for symptomatic treatments that improve cognition, memory, and daily...